

# Newport Beach and Birch Street

---

## Clinical Research Treatment Trial Flowchart

**AML NEWLY DIAGNOSED: NON-INTENSIVE**

UCI 21-216

Giltertinib+Venetoclax+Azacitidine in patients w/ FLT3 mutant AML not eligible for intensive induction chemotherapy  
FLT3 mutation

Mechanism: FLT3 inhibitor

PI: Jeyakumar  
Coord: S. Osorio  
Accrual: 1/5

**POLYCYTHEMIA VERA**

UCI 21-204

ISIS702843 in patients w/ PD-PC

Mechanism: Antisense oligonucleotide specific for human transmembrane protease serine 6

PI: Fleischman  
Coord: K. McAbee  
Accrual: 1/5

**CLL RELAPSED/REFRACTORY: 2L+**

UCI 21-209

LOXO-305 + Venetoclax and Rituximab vs. Venetoclax and Rituximab in previously treated CLL/SLL

Mechanism: BTK inhibitor + BCL2 inhibitor + CD20 marker

PI: Coombs  
Coord: A. Saatchi  
Accrual: 2/3

**CLL NEWLY DIAGNOSED: HIGH RISK**

SWOG S1925

Venetoclax+Obnutumab early intervention vs. delayed therapy in asymptomatic high-risk CLL/SLL

Mechanism: BCL2 inhibitor +anti-CD20 monoclonal antibody

PI: Coombs  
Coord: A. Saatchi  
Accrual: 1/10

**GASTRIC/GEJ: NEWLY DIAGNOSED METASTATIC**

**ECOG EA2183**

(SOC + XRT)

PI: Seyedin  
Coord: J. Koff  
Accrual: 0/7

**UCI 21-193**  
(FGFR inhibitor + mFOLFOX6 + antiPD-L1 (nivolumab))

PI: Dayyani  
Coord: M. Nguyen  
Accrual: 1/12

**GASTRIC/GEJ: NEOADJUVANT**

**UCI 21-191**  
(SOC therapy with ctDNA testing)

PI: Dayyani  
Coord: A. Luna  
Pending activation

## NON-TREATMENT/BASIC SCIENCE

UCI 18-136

PI: Parajuli  
Coord: B. Sanchez/C. Carlton  
Accrual: 65/100

UCI 17-05 (BRCA1 -/+)

PI: Parajuli  
Coord: B. Sanchez  
Accrual: 48/75

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

## ADJUVANT

ALLIANCE A011801 (HER2+)

Antibody drug conjugate + kinase inhibitor

PI: Parajuli  
Coord: Alexis Chavez  
Accrual: 4/5

UCI 22-141 (TNBC)

PDL-1 inhibitor

PI: Parajuli  
Coord: J. Miranda  
Accrual: 0/5

## 1L METASTATIC

## 2L METASTATIC

## 3L METASTATIC

ETCTN 10546 (TNBC)

Cytidine deaminase (CDA) inhibitor + nucleoside hypomethylating agent (HMA)  
 PI: Parajuli; Coord: A. Chavez  
 Accrual: 1/5

UCI 19-145 (HR+/HER2-)

CDK 4/6 inhibitor + ER Regulator + Aromatase Inhibitor  
 PI: Mehta; Coord: S. Ruiz  
 Accrual: 11/20

UCI 21-212 (TNBC)

Antibody drug conjugate  
 PI: Parajuli; Coord: A. Chavez  
 Accrual: 0/3

UCI 22-139 (HR+/HER2-)

PI3K/mTOR inhibitor  
 PI: Parajuli; Coord: Alexis Chavez  
 Accrual: 3/5

UCI 22-114 (ER+/HER2-)

Proteasome-mediated degradation  
 PI: Parajuli; Coord: Alexis Chavez  
 Accrual: 3/5

## HCC: LOCOREGIONAL

### UCI 19-49

Cabo + Ipi/Nivo + TACE

PI: Dayyani  
Coord: Han Nguyen  
Accrual: 17/35

## HCC: 1-3L

### UCI 22-106

STAT3 ± Pembrolizumab or ± Atezolizumab and Bevacizumab

PI: Dayyani  
Coord: H. Nguyen  
Accrual: 5/10

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

## PANCREATIC: BORDERLINE/LOCALLY ADVANCED

### ETCTN 10366

M3814 (Peposertib) + radiation therapy

PI: Dayyani  
Coord: J. Balangue  
Accrual: 4/8

MELANOMA: NON-TREATMENT

UCI 19-135

DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)

PI: Yamamoto  
Coord: A. Reipolska  
Accrual: 76/90

SARCOMA: RECURRENT

ETCTN 10556

Ipilimumab and Nivolumab +/- Cabozantinib

PI: Chow  
Coord: B. Huynh  
Accrual: 1/5

**KRAS**UCI 22-75

KRAS targeted Vaccine

PI: Valerin  
Coord: M. Duron  
Accrual: 2/7 Open to Accrual Low Accruing Pending Activation/Suspended**CLDN18.2**UCI 21-10

Bispecific antibody (anti-CLDN18.2 + anti-4-1BB)

PI: Dayyani  
Coord: K. Ghio  
Accrual: 12/17**NON-TREATMENT**UCI 20-101

(Biospecimen Collection for patients planned to start treatment)

PI: Senthil  
Coord: J. Koff  
Accrual: 53/80